Please login to the form below

baricitinib

This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

One of the drugs identified using the DRIAD method was Eli Lilly’s Olumiant(baricitinib), which will be investigated in a clinical trial for patients with subjective cognitive complaints, mild cognitive

Latest news

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Last week, Eli Lilly and Incyte’s repurposed arthritis treatment baricitinib also scored an EUA in combination with Gilead’s remdesivir for the treatment of hospitalised COVID-19 patients.
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Patients treated with the baricitinib/remdesivir regimen were also more likely to have a better clinical status at day 15 compared to remdesivir monotherapy. ... 35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with
Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

inhibitor Olumiant (baricitinib) for the novel coronavirus.
Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

In addition to its studies of the COVID-19 targeting antibodies, Lilly is also undertaking clinical development of its JAK inhibitor Olumiant (baricitinib) in combination with Gilead’s remdesivir in patients
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), evaluated a 4mg dose of Olumiant (baricitinib) given alongside remdesivir versus remdesivir alone ... This data allows us to better understand

More from news
Approximately 10 fully matching, plus 39 partially matching documents found.

Latest Intelligence

NICE – but not enough

A great illustration of why this is unfortunately a myth can be seen in Figure 1, which charts the formulary adoption of Olumiant (baricitinib) – Lilly’s once-daily pill for moderate
AI: the smart money is on the smart thinking

Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive Salary

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Medical Writer: Competitive Salary

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Associate Account Director: Competitive Salary

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Account Manager: Competitive Salary

Senior Account Executive: Competitive Salary

PMHub

Add my company

11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Empowering patients empowers results: Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials: What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training: Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...